MODERN NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS FOR INFLAMMATORY BOWEL DISEASE TREATMENT: A COMPREHENSIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.4(48).2025.4489Keywords:
Inflammatory Bowel Disease, Nanotechnology, Targeted Drug Delivery, Nanoparticles, Ulcerative Colitis, Macrophage Polarization, ROS Scavenging, Immune ModulationAbstract
Background: Inflammatory bowel disease (IBD), principally comprising ulcerative colitis (UC) and Crohn’s disease (CD), represents a growing global health burden characterized by chronic, relapsing inflammation of the gastrointestinal tract. The pathogenesis is multifactorial, involving genetic susceptibility, gut microbiota dysbiosis, and a dysregulated immune response. Current pharmacological strategies, including aminosalicylates, corticosteroids, immunomodulators, and biologics, are effective but often limited by non-specific distribution, low local bioavailability due to rapid gastrointestinal clearance, and severe systemic adverse effects such as immunosuppression and hepatotoxicity. Consequently, there is an urgent clinical need for novel therapeutic approaches that can deliver drugs precisely to the inflamed mucosa while minimizing systemic exposure. Nanotechnology has emerged as a transformative strategy to address these challenges by enabling targeted, controlled, and efficient drug delivery.
Objective: This narrative review aims to provide a comprehensive evaluation of the state-of-the-art nanotechnology-based drug delivery systems (DDSs) for IBD treatment. It critically analyzes specific targeting mechanisms-including passive accumulation via the epithelial enhanced permeability and retention (eEPR) effect, active receptor targeting, and stimuli-responsive release-and assesses the therapeutic efficacy of novel nanocarriers loading a wide range of bioactive agents.
Materials and Methods: A structured narrative review was conducted based on an extensive analysis of scientific literature published between 2015 and 2025. The review included original in vitro and in vivo studies focusing on organic (polymeric, lipid, hydrogel), inorganic (metallic, silica), and biomimetic nanocarriers. Data extraction prioritized physicochemical properties (size, charge), specific targeting ligands (e.g., hyaluronic acid, mannose, folate), and the modulation of key inflammatory pathways (NF-κB, ROS scavenging, cytokine production).
Results: The analysis revealed that nanoparticle-based systems significantly enhance drug accumulation in inflamed colonic tissues compared to free drugs. Passive targeting strategies leveraging the eEPR effect and charge-dependent mucoadhesion demonstrated improved retention times. Active targeting utilizing ligands for CD44 (hyaluronic acid), mannose receptors (CD206), and transferrin receptors facilitated superior cellular uptake by activated macrophages and epithelial cells. Innovative stimuli-responsive formulations, such as pH-sensitive liposomes, ROS-responsive nanozymes (e.g., cerium oxide, manganese-polyphenol), and enzyme-degradable polysaccharide carriers, provided precise release profiles triggered by the pathological microenvironment. These systems effectively restored the intestinal barrier, significantly reduced pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and mitigated oxidative stress in murine colitis models. Furthermore, natural compounds like curcumin and resveratrol showed dramatically improved bioavailability and therapeutic potential when encapsulated in nanocarriers.
Conclusion: Nanotechnology-based DDSs represent a promising frontier in IBD therapy, offering a paradigm shift from systemic immunosuppression to precision local treatment. By maximizing local drug concentration and minimizing off-target effects, these systems address the fundamental limitations of current pharmacotherapy. While preclinical results are highly encouraging, further research focusing on long-term safety, scalable manufacturing, and rigorous clinical validation is essential to translate these innovations into standard clinical practice.
References
Guan Q. (2019). A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. Journal of immunology research, 2019, 7247238. https://doi.org/10.1155/2019/7247238
Raine, T., Bonovas, S., Burisch, J., Kucharzik, T., Adamina, M., Annese, V., Bachmann, O., Bettenworth, D., Chaparro, M., Czuber-Dochan, W., Eder, P., Ellul, P., Fidalgo, C., Fiorino, G., Gionchetti, P., Gisbert, J. P., Gordon, H., Hedin, C., Holubar, S., Iacucci, M., … Doherty, G. (2022). ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's & colitis, 16(1), 2–17. https://doi.org/10.1093/ecco-jcc/jjab178
Hua, S., Marks, E., Schneider, J. J., & Keely, S. (2015). Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine : nanotechnology, biology, and medicine, 11(5), 1117–1132. https://doi.org/10.1016/j.nano.2015.02.018
Liu, P., Gao, C., Chen, H., Vong, C. T., Wu, X., Tang, X., Wang, S., & Wang, Y. (2021). Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies. Acta pharmaceutica Sinica. B, 11(9), 2798–2818. https://doi.org/10.1016/j.apsb.2020.11.003
Gao, J., Li, J., Luo, Z., Wang, H., & Ma, Z. (2024). Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment. Drug design, development and therapy, 18, 2921–2949. https://doi.org/10.2147/DDDT.S461977
Lin, Z., Zhao, Z., Lin, X., Yang, Z., Wang, L., Xi, R., & Long, D. (2025). Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems. Drug delivery, 32(1), 2544689. https://doi.org/10.1080/10717544.2025.2544689
Cui, M., Zhang, M., & Liu, K. (2021). Colon-targeted drug delivery of polysaccharide-based nanocarriers for synergistic treatment of inflammatory bowel disease: A review. Carbohydrate polymers, 272, 118530. https://doi.org/10.1016/j.carbpol.2021.118530
Liu, H., Lv, H., Duan, X., Du, Y., Tang, Y., & Xu, W. (2023). Advancements in Macrophage-Targeted Drug Delivery for Effective Disease Management. International journal of nanomedicine, 18, 6915–6940. https://doi.org/10.2147/IJN.S430877
Liu, Y., Huang, J., Li, S., Li, Z., Chen, C., Qu, G., Chen, K., Teng, Y., Ma, R., Wu, X., & Ren, J. (2024). Advancements in hydrogel-based drug delivery systems for the treatment of inflammatory bowel disease: a review. Biomaterials science, 12(4), 837–862. https://doi.org/10.1039/d3bm01645e
Wang, D., Jiang, Q., Shen, R. et al. ROS-responsive nanoparticles targeting inflamed colon for synergistic therapy of inflammatory bowel disease via barrier repair and anti-inflammation. Nano Res. 17, 5409–5423 (2024). https://doi.org/10.1007/s12274-024-6435-6
Yang, H., Wang, Z., Li, L., Wang, X., Wei, X., Gou, S., Ding, Z., Cai, Z., Ling, Q., Hoffmann, P. R., He, J., Liu, F., & Huang, Z. (2024). Mannose coated selenium nanoparticles normalize intestinal homeostasis in mice and mitigate colitis by inhibiting NF-κB activation and enhancing glutathione peroxidase expression. Journal of nanobiotechnology, 22(1), 613. https://doi.org/10.1186/s12951-024-02861-2
Xiao, B., Xu, Z., Viennois, E., Zhang, Y., Zhang, Z., Zhang, M., Han, M. K., Kang, Y., & Merlin, D. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular therapy : the journal of the American Society of Gene Therapy, 25(7), 1628–1640. https://doi.org/10.1016/j.ymthe.2016.11.020
Basak, A., Ghosh, S., Ganguly, D., Garain, S., Ghosh, R., Choudhury, A., Deka, H., & Sarmah, J. (2023). Current Trends and Future Perspectives of Natural Polymer Loaded Nanoparticle Based Drug Delivery System for the Management of Inflammatory Bowel Disease. Journal of Applied Pharmaceutical Research, 11(4), 1–9. https://doi.org/10.18231/j.joapr.2023.11.4.1.9
Altaf, S., Zeeshan, M., Ali, H., Zeb, A., Afzal, I., Imran, A., Mazhar, D., Khan, S., & Shah, F. A. (2024). pH-Sensitive Tacrolimus loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 204, 114461. https://doi.org/10.1016/j.ejpb.2024.114461
Cai, X., Wang, X., He, M., Wang, Y., Lan, M., Zhao, Y., & Gao, F. (2021). Colon-targeted delivery of tacrolimus using pH-responsive polymeric nanoparticles for murine colitis therapy. International journal of pharmaceutics, 606, 120836. https://doi.org/10.1016/j.ijpharm.2021.120836
Yan, J. H., Liang, C. X., Ma, R. R., Li, B. J., Chen, Q. W., Li, W., Zeng, X., & Zhang, X. Z. (2025). Sulfasalazine-Loaded Copper-Tannic Acid Coordination Nanozyme Enables ROS Scavenging and Immunomodulation for Inflammatory Bowel Disease Therapy. Advanced healthcare materials, 14(26), e2403738. https://doi.org/10.1002/adhm.202403738
Dong, L., Wang, W., Zheng, H., Sun, Y., & Han, S. (2025). Construction of Mn2+-Polyphenol Nanoparticles and Its Application in the Treatment of Ulcerative Colitis. ACS applied bio materials, 8(5), 4367–4382. https://doi.org/10.1021/acsabm.5c00471
Zhang, X., Yang, H., He, Y., Zhang, D., Lu, G., Ren, M., Lyu, Y., Yuan, Z., & He, S. (2025). Yeast-Inspired Orally-Administered Nanocomposite Scavenges Oxidative Stress and Restores Gut Immune Homeostasis for Inflammatory Bowel Disease Treatment. ACS nano, 19(7), 7350–7369. https://doi.org/10.1021/acsnano.4c18099
Li, Y., Chen, T., Chen, L., Wu, D., & Hu, J. (2024). Construction of hyaluronic acid-functionalized magnolol nanoparticles for ulcerative colitis treatment. International journal of biological macromolecules, 268(Pt 2), 131920. https://doi.org/10.1016/j.ijbiomac.2024.131920
Li, Q., Lin, L., Zhang, C., Zhang, H., Ma, Y., Qian, H., Chen, X. L., & Wang, X. (2024). The progression of inorganic nanoparticles and natural products for inflammatory bowel disease. Journal of nanobiotechnology, 22(1), 17. https://doi.org/10.1186/s12951-023-02246-x
Meng, Z. W., Chang, B., & Sang, L. X. (2024). Use of curcumin and its nanopreparations in the treatment of inflammatory bowel disease. World journal of gastroenterology, 30(3), 280–282. https://doi.org/10.3748/wjg.v30.i3.280
Zhao X, Su W, Zhang X, Tan M. Visual foodborne nanoparticles for oral site-specific delivery of anthocyanins in the treatment of inflammatory bowel disease. Materials today Nano. 2023;24:100431. https://doi.org/10.1016/j.mtnano.2023.100431
Gowd, V., Kanika, Jori, C., Chaudhary, A. A., Rudayni, H. A., Rashid, S., & Khan, R. (2022). Resveratrol and resveratrol nano-delivery systems in the treatment of inflammatory bowel disease. The Journal of nutritional biochemistry, 109, 109101. https://doi.org/10.1016/j.jnutbio.2022.109101
Mohan, L. J., Daly, J. S., Ryan, B. M., & Ramtoola, Z. (2023). Oral infliximab nanomedicines for targeted treatment of inflammatory bowel diseases. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 183, 106379. https://doi.org/10.1016/j.ejps.2023.106379
Chen, G., Yang, F., Fan, S., Jin, H., Liao, K., Li, X., Liu, G. B., Liang, J., Zhang, J., Xu, J. F., & Pi, J. (2022). Immunomodulatory roles of selenium nanoparticles: Novel arts for potential immunotherapy strategy development. Frontiers in immunology, 13, 956181. https://doi.org/10.3389/fimmu.2022.956181
Downloads
Published
Issue
Section
License
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
